Member Info for Saxondale

Yes CB . Every big Pharma has an Oncology arm that is looking for new potential drugs that are close to market , derisked , and especially those that are a platform drug with multiple uses .

The MDS trial is just the tip of the iceberg .

Azacitidine is owned by Bristol Myers Squib - they must surely be in the mix . Their drug has been the leader in MDS for 17 years - but it runs out of patent in about 5 yrs . Plus despite it being the leader - its pretty ineffective on its own .

I really can see a bidding war coming .

Https://www.fda.gov/about-fda/oncology-center-excellence/project-frontrunner

Earlier access to new therapies: Initiating the clinical investigation of new therapies in an earlier treatment setting can provide more patients the opportunity to receive the investigational agent early enough in the disease course when disease-related factors do not preclude participation in the trial, and when the treatment has the potential to alter the course of the disease more effectively.

Facilitate engagement with drug sponsors during drug development to develop and implement strategies to support approvals in early clinical setting.

A long way to go here . Many ( including me , are still not in profit here on paper yet , despite the rise )

Long term holders will want to see this to its logical conclusion .

I know Markku got some slating for his ' add a zero ' comment , but in reality this is what we are looking at .

It looks like yes they have a FDA approved pathway to run with a P3 - but they can do it with front line high risk MDS patients - rather than the refractory ones - so a bigger patient population - and quicker recruitment .

I guess maybe the short survival times of many refractory patients may have made a blind placebo trial a little pointless ( ie for those who have to take the placebo when Bex is offering so much of a difference ) , or for other reasons.

They don't expect big numbers by the looks of it to achieve P3 approval either - and the data from patients comes very quickly - so it will be months not a year or more like some P3 trials.

So this will open up Bex to a much bigger population of MDS patients - not just failed refractory ones .

HUGE .

£3.60 with 65m shares gave us a Mcap of about £235m .

With 105m shares that Mcap gives us about £2.30 in todays money - still not shabby - but back then we didn't have FDA green light or as much spectacular Bexmab data - and we weren't financially sound ( ie placing always on the horizon) , so realistically there is no reason why we shouldn't have an Mcap of £350 to 400m - which gets us back to the £3.50 area .

All to play for - and as far as we know there are ' multiple' partners in discussion .

It may well do Western . Faron wanted to get this far alone , and we've had to suffer some serious dilution - but they have no wish to take this to market alone . They want a partner - who can do the heavy lifting going forward .

Small free float , lots of sticky hands , and fully derisked project . Its looking good .

Avacata is making a great recovery - from that terrible placing and shorting action . I've done ok there too - I got my average down to about 63p there . So 2024 could be a good year allround if they both explode !

FDA proposals 'exceeded' Farons expectations .

This is about the best response from FDA you could have hoped for in my opinion .

The last piece of information that a potential partner needed - whats the plan to get it to market ? - has just been answered . The bonus is that it will be quicker than anticipated , and targeting more patients .

This will be music to the ears of any Big Pharma looking to partner up .

Expect more details on the 15th - but for now this is just brilliant news .

Not saying the SP will double today - but we are firmly on track now to successfully partner and get Bex on the market .

Well done !!

Just sitting tight waiting for the next developments CB .

I think the Solar Panel scientist won the award in our category today - anyway - just a side story and great to be in the spotlight .

We'll just have to wait for the really big prize coming up lol .

Just to add that when I said Timo has been pumping money in , he does have something to show for it I guess , 16 million shares ( not sure what his average is - rough guess maybe £1.50 or a bit more maybe even £2.00 )

It's times like this you have to look not at the share price , but how many actual shares you have . I've got double what I had a year ago . A big commitment for me - and I have no plans on selling many ( or any preferably ) until we are well past the next milestone .

I wouldn't read too much into these transactions Santhi . All day you could sell for 93-95p ( although why would you ? ) .

Huge volumes on Naz - obviously something to do with the new shares arriving or shuffling going on .

Best ignore the SP for a few weeks . These things don't happen like a magic wand . We now have funds . That isn't going to translate into some miracle trebling of the SP the next day .

Investors have now loaded up at a massive discount , but we have also taken a massive dilution too , so as £8 in the old days became about £4.50 ( 30 -60m shares roughly ), so as Q says £2.50 now becomes £1.38 ( 65m - 105m)

But £2.50 was seen as a fair price when we had no funding arranged ( but holding up due to hope that a deal was imminent)

When it transpired that no deal was going to land before funding - obviously the market conditions ( terrible) dictated a terrible fundraise SP . Similar situations have occured recently in other companies (AVCT /POLX etc).

Faron were running on fumes - personally I don't know why they left it so late or ran it so tight - maybe they were naive and had the rug pulled over some kind of deal - we will never know . Either way - the big cornerstone investors perhaps ditcated this low price - i.e the likes of Timo have been pumping money in for years with not much to show for it .

So one last cash call - everyone gets a cheap deal - including all LTH's . Fair enough .

Now we let them get on with converting our extra investment cash into something concrete . We have all put our trust in them . So we now wait for news on FDA , further trial data , and partner news .

The SP may well bash around here for months . The big Instos wont worry what the SP is on a daily basis . So long as they have what they want .

My expectation is that we will float around £1 for a bit , until the opportunists are flushed out , then start a steady build in anticipation of partner news .

CB my take is that there are multiple interested Big Pharma . BMS , Bayer , etc - they are all looking to expand their cancer oncology portfolios with new platforms . Haematological treatments especially .

Bex with MDS - serves up a ready to go entry drug to get them rolling - then there are all the other possibilities with combinations for other existing treatments . Thats why Faron have held back from taking any sub par deal up until now , because they know what its potential is . With Bexmab P2 done , and an FDA green light - they should finally get a proper deal - the product is de risked - so that will command a higher price .

We've had to suck it up at the last hurdle with this fundraise - but once Bex gets commercialised - and Faron finally start getting income - its a whole new level .

Just re=reading that - maybe I wont get that extra 20% ?

Maybe they are just reserved until they dish them out - then I get a refund on those they couldn't fulfill .

Either way , I'm not exactly short of Faron shares at the moment lol .

No surprise it was oversubscribed .

Expected - but relief that its all successfully done now .

Also looks like I got what I asked for ( 20% more than my allotment ).

Timo had over 3.5 million - taking his total to over 16million now (15% of company)

Also shows by quick glance that the Finnish side of investors is by far the bigger compared to UK ( nearly 8m shares to Finland vs only about 2m in UK ) .

And 2/3rds of the fundraise was to Institutional Investors - another big positive .

Strickly , I think we all have those thoughts . I've done alot of thinking about Faron recently . About chucking good money after bad . Is 85p a gift ? I too have little to show for many of my investments . Some I have walked away from . Two I have stuck with in size is Faron and GGP . Eventually I believe we will see rewards . So I have doubled down in both . I won't starve if both implode , but despite AIMs ability to swallow peoples money , I feel these two have the best chance . Faron's Finnish investor base is also another positive . We aren't totally at the whim of AIM . I really hope that in a years time we can look back and see that by holding on , we did the right thing . Good luck .

I sold 2 days ago , and just bought back in again now . Lucky I guess , but these presentations are pretty much always a passion killer , no matter who does them in Bio pharma . Every word can be take the wrong way . I haven't even watched it yet . I reckon if you did that for every company on Investormeets , you make 10-20% just by selling and buying back .

Mcap of £11m - with the potential market . Huge opportunity I'd say .

Someone get the rocket meme out , and make sure its pointing the right way this time

Morning all . Way back my guess was £1.37 I think . Still got my shares ( average 2p) .

Time to dust off the pirate hat .

The Nas is still trading 20% above fundraise price which is significant . I think perhaps today reflects a few doing the ' sell and buy back and make a bit ' as a few trading platforms loaded the offer up to PI's . I expect it to hover in the 90's until its all wrapped up , then its a case of supply and demand . Any good news will put some wind in our sails .

Funny , I was told last week that my broker wasn't taking part , but just now they landed in my account too , so I can take up the offer too . Happy Days .

Good info there Itsall .

Tom Erik now has nearly 5m shares , so keeping his approx 5% ownership .